Details of the Drug
General Information of Drug (ID: DMTV4L0)
| Drug Name |
Myricetin
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
myricetin; 529-44-2; Cannabiscetin; Myricetol; Myricitin; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one; 3,3',4',5,5',7-Hexahydroxyflavone; 3,5,7,3',4',5'-Hexahydroxyflavone; UNII-76XC01FTOJ; NSC 407290; CCRIS 5838; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-1-benzopyran-4-one; 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one; EINECS 208-463-2; NSC407290; CHEMBL164; NSC-407290; BRN 0332331; 76XC01FTOJ
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 318.23 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 1.2 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 6 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 8 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Drug-Molecule Activity Atlas (DMA)NEW | Click to Jump to the Detailed DMA Information of This Drug | ||||||||||||||||||
| Drug Pharmacogenomic Perturbation (DPP)NEW | Click to Jump to the Detailed DPP Information of This Drug | ||||||||||||||||||
| Drug ADMET Endpoint Profile (DAE)NEW | Click to Jump to the Detailed DAE Information of This Drug | ||||||||||||||||||
| Combinatorial Drugs (CBD) | Click to Jump to the Detailed CBD Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
![]() Drug Off-Target (DOT) |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||
References



